1,289 results on '"Day, John W."'
Search Results
102. Water Quality Analysis of a Freshwater Diversion at Caernarvon, Louisiana
103. Enhancing mud supply from the Lower Missouri River to the Mississippi River Delta USA: Dam bypassing and coastal restoration
104. Approaches to defining deltaic sustainability in the 21st century
105. Large infrequently operated river diversions for Mississippi delta restoration
106. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
107. Rapid Deterioration of a Salt Marsh in Venice Lagoon, Italy
108. Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1
109. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)
110. Assessing Bulbar Function in Spinal Muscular Atrophy Using Patient-Reported Outcomes
111. Efficacy and Safety of Avalglucosidase Alfa in Patients with Late-Onset Pompe Disease after 97 Weeks:A Phase 3 Randomized Clinical Trial
112. 2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants
113. Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy
114. Expanding the muscle imaging spectrum in dysferlinopathy: description of an outlier population from the classical MRI pattern
115. Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy
116. Resilience of Natural Systems and Human Communities in the Mississippi Delta: Moving beyond Adaptability Due to Shifting Baselines
117. Assessment of disease progression in dysferlinopathy: A 1-year cohort study
118. DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A Results.
119. 2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants
120. Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks of treatment during the COMET trial
121. AT845 gene replacement therapy for late onset Pompe disease: An update on safety and preliminary efficacy data from FORTIS, a phase I/II open-label clinical study
122. O19: Integrated analyses of data from clinical trials of delandistrogene moxeparvovec gene therapy in DMD*
123. The coming perfect storm: Diminishing sustainability of coastal human–natural systems in the Anthropocene
124. Humanizing the mdx mouse model of DMD: the long and the short of it
125. Consensus-based care recommendations for adults with myotonic dystrophy type 1
126. Water quality of a coastal Louisiana swamp and how dredging is undermining restoration efforts
127. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial
128. A review of issues related to formation, deterioration and restoration of the Chenier Plain, Mississippi River Delta, LA - Combining nature based and engineered approaches
129. Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation–Sponsored Workshop
130. Carbon Sequestration at a Forested Wetland Receiving Treated Municipal Effluent
131. Fate of Soil Organic Carbon During Wetland Loss
132. Water T2 could predict functional decline in patients with dysferlinopathy
133. Author comment: The coming perfect storm: Diminishing sustainability of coastal human–natural systems in the Anthropocene — R0/PR1
134. Exome sequencing identifies a DNAJB6 mutation in a family with dominantly-inherited limb-girdle muscular dystrophy
135. Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function
136. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
137. Spatial and Temporal Variations in Nutrients and Water-Quality Parameters in the Mississippi River-Influenced Breton Sound Estuary
138. Energy and Climate – Global Trends and Their Implications for Delta Restoration
139. Large Infrequently Operated River Diversions for Mississippi Delta Restoration
140. Optimum Use of Fresh Water to Restore Baldcypress – Water Tupelo Swamps and Freshwater Marshes and Protect Against Salt Water Intrusion: A Case Study of the Lake Pontchartrain Basin
141. Summary and Conclusions
142. The Costs and Sustainability of Ongoing Efforts to Restore and Protect Louisiana’s Coast
143. A Brief History of Delta Formation and Deterioration
144. Introduction – Changing Conditions in the Mississippi Delta from 1700 to 2100 and Beyond: Avoiding Folly
145. Using Natural Wetlands for Municipal Effluent Assimilation: A Half-Century of Experience for the Mississippi River Delta and Surrounding Environs
146. Conservation and Use of Coastal Wetland Forests in Louisiana
147. Tidal Freshwater Forested Wetlands: Future Research Needs and an Overview of Restoration
148. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
149. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
150. The Energy Pillars of Society: Perverse Interactions of Human Resource Use, the Economy, and Environmental Degradation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.